文献速递骨软组织肉瘤与黑色素瘤

随机III期试验中肿瘤浸润淋巴细胞与伊匹木单抗治疗转移性黑色素瘤患者的健康相关生活质量比较

Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial.
PubMed 文献 · Ann Oncol · 2025-06-18

这项多中心随机III期试验评估转移性黑色素瘤患者接受肿瘤浸润淋巴细胞研究性药品(TIL-IMP)或伊匹木单抗(IPI)治疗后的健康相关生活质量。168例患者按1:1随机分组,143例有基线生活质量评分。TIL-IMP组在24周时整体健康状况和情绪功能评分较高,疲乏和疼痛评分较低,但恶心呕吐评分略高,EQ-5D评分较高;这些差异有统计学意义但未被认为有临床意义。IES评分未观察到TIL-IMP较IPI影响更大的假设。结论为两组生活质量相似,TIL-IMP组随时间有更好趋势。

要点

  • TIL-IMP组24周整体健康状况78.2 vs IPI组73.9(P<0.05),差异无临床意义。
  • TIL-IMP组24周疲乏25.0 vs IPI组32.4(P<0.05),疼痛13.7 vs 17.6(P<0.05)。
  • TIL-IMP组24周恶心呕吐7.5 vs IPI组5.2(P<0.05),IES评分11.8 vs 17.4(P<0.05)。

核心结论

  • 转移性黑色素瘤患者接受TIL-IMP治疗与IPI单药治疗的生活质量相似,TIL-IMP组随时间有更好生活质量结局的迹象。
  • 作者认为持续随访对评估长期生活质量和推广至更大人群至关重要,以帮助指导个体化治疗决策。

研究设计与样本

  • 多中心、随机、III期试验(NCT02278887),转移性黑色素瘤(不可切除IIIC-IV期)患者按1:1随机接受TIL-IMP或IPI治疗。
  • 共168例患者随机,143例(85%)有基线生活质量评分可计算;其中TIL-IMP组75例(89%),IPI组73例(87%)。
  • 生活质量采用EORTC QLQ-C15-PAL、EQ-5D-3L和IES量表测量,使用广义估计方程模型评估,并进行敏感性分析评估脱落假设。

主要发现

  • 24周时TIL-IMP组整体健康状况评分78.2 vs IPI组73.9(P<0.05),情绪功能评分85.9 vs 77.9(P<0.05)。
  • 24周时TIL-IMP组疲乏评分25.0 vs IPI组32.4(P<0.05),疼痛评分13.7 vs 17.6(P<0.05),恶心呕吐评分7.5 vs 5.2(P<0.05)。
  • 24周时TIL-IMP组EQ-5D评分0.89 vs IPI组0.83(P<0.05),IES评分11.8 vs 17.4(P<0.05)。
  • 上述统计学显著差异未被认为有临床意义;敏感性分析显示相似结果。

关键数值与推荐

  • TIL-IMP组24周整体健康状况78.2 vs IPI组73.9(P<0.05)。
  • TIL-IMP组24周情绪功能85.9 vs IPI组77.9(P<0.05)。
  • TIL-IMP组24周疲乏25.0 vs IPI组32.4(P<0.05),疼痛13.7 vs IPI组17.6(P<0.05)。
  • TIL-IMP组24周恶心呕吐7.5 vs IPI组5.2(P<0.05)。
  • TIL-IMP组24周EQ-5D 0.89 vs IPI组0.83(P<0.05),IES 11.8 vs IPI组17.4(P<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to assess health-related quality of life (HRQoL) in patients with metastatic melanoma treated with a tumor-infiltrating lymphocyte investigational medicinal product (TIL-IMP) or ipilimumab (IPI) after failure of first- or second-line treatment. PATIENTS AND METHODS: In a multicenter, randomized, phase III trial, patients with metastatic melanoma (unresectable stage IIIC-IV) were randomized to TIL-IMP or IPI treatment (NCT02278887). HRQoL was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative Care (EORTC QLQ-C15-PAL), EuroQol 5D-3L (EQ-5D), and the Impact of Event Scale (IES). HRQoL outcomes were evaluated using a generalized estimating equations model. Sensitivity analyses were carried out to assess dropout assumptions. Results were interpreted for statistically and clinically significant differences. RESULTS: Of 168 patients randomized 1 : 1, n = 143 baseline HRQoL scores (85%) were calculated. Of these, 75 (89%) were in the TIL-IMP group and 73 (87%) in the IPI group. TIL-IMP-treated patients reported higher global health status scores at week 24 compared with IPI-treated patients (78.2 versus 73.9; P < 0.05) and higher emotional functioning (85.9 versus 77.9; P < 0.05) scores. Patients treated with TIL-IMP had significantly lower fatigue (25.0 versus 32.4; P < 0.05) and pain (13.7 versus 17.6; P < 0.05) scores at week 24, but marginally higher nausea and vomiting (7.5 versus 5.2; P < 0.05) symptom scores. EQ-5D scores were also higher in the TIL-IMP group (0.89 versus 0.83; P < 0.05). These statistically significant differences were not considered clinically meaningful. The hypothesized higher impact of the more intensive TIL-IMP treatment compared with IPI was not observed, according to IES scores (11.8 versus 17.4; P < 0.05 at 24 weeks). Sensitivity analyses showed similar results. CONCLUSIONS: Patients with metastatic melanoma treated with TIL-IMP experienced similar HRQoL compared with IPI monotherapy, with indications of better HRQoL outcomes over time. Ongoing follow-up is essential to assess longer-term HRQoL and its generalizability to a larger patient population to help guide personalized treatment decisions.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Ten Ham RMT, Rohaan MW, Egeler M, et al. Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial. Ann Oncol. 2025. PMID: 40541863. doi:10.1016/j.annonc.2025.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。